Evidence reviewed: 8 November 2026. Human papillomavirus (HPV) is a group of common viruses transmitted through intimate skin-to-skin contact. Most infections clear without causing symptoms, but persistent infection with certain high-risk HPV types can lead to cervical, anal, oropharyngeal, vaginal, vulvar and penile cancers. Other types cause genital warts. HPV vaccination is a highly effective cancer-prevention measure when given before exposure to vaccine-covered HPV types, and it benefits people of different sexes. Vaccination prevents new HPV infections—it does not treat existing HPV infection, genital warts or cancer [1-3].
What is HPV, and how can it cause cancer?
HPV is a family of DNA viruses that infect skin and mucosal tissues. Intimate sexual contact is a common route of transmission, including contact without penetrative sex. Many people never know they have been infected. A healthy immune system often controls infection within one or two years, but some high-risk HPV infections persist. Persistent infection can disrupt normal regulation of cell growth and, over time, contribute to precancerous changes and invasive cancer [1,4].
The most important cancer-associated types include HPV 16 and HPV 18; these contribute to a large proportion of cervical cancers worldwide. Types 6 and 11 are associated with most genital warts but are not the principal causes of HPV-related cancers. It usually takes years—sometimes decades—for persistent high-risk infection to progress to cancer; a positive HPV test does not mean someone has cancer [1,4].
Which cancers and conditions can HPV cause?
- Cervical cancer and precancerous cervical changes.
- Some anal, vulvar, vaginal and penile cancers.
- Some oropharyngeal cancers, especially in the tonsils and base of the tongue.
- Genital warts, mainly from low-risk viral types.
CDC estimates that HPV vaccination could prevent more than 90% of HPV-attributable cancers under effective coverage and protection assumptions [1,4]. This does not mean that every case of cancer is preventable by vaccination or that vaccination replaces screening.
How do HPV vaccines work?
HPV vaccines use virus-like particles (VLPs) made from the major HPV capsid protein, L1. VLPs look similar enough to the viral shell to provoke a strong immune response, but they contain no infectious HPV genome and cannot cause HPV infection. Vaccination induces antibodies that help prevent infection when a vaccinated person encounters a covered HPV type in the future [3].
The nine-valent HPV vaccine targets types 6, 11, 16, 18, 31, 33, 45, 52 and 58. Vaccine availability differs by country; bivalent, quadrivalent and nine-valent products have been used in different immunization programmes. In the United States, the nine-valent product is used. The best individual schedule depends on which product is authorized and the local immunization programme [2,3].
Who should receive HPV vaccination?
Vaccination is most effective before HPV exposure, so routine programmes prioritize preteens and young adolescents. It is routinely recommended for boys as well as girls in the US, while some other countries prioritize girls and also offer vaccination to boys depending on national policy and resources [2,3].
United States CDC recommendations
- Routine: all children at age 11–12 years, with the option to start from age 9.
- Catch-up: vaccination for eligible people through age 26 who were not adequately vaccinated.
- Ages 27–45: some adults may benefit, but vaccination is based on shared clinical decision-making rather than a universal recommendation.
- HPV vaccination is generally not recommended after age 45 under US guidance [2].
WHO guidance and differences between countries
The World Health Organization supports one- or two-dose schedules for girls aged 9–14 years in national programmes, and its 2022 position paper also provides age-specific options for older adolescents and adults. The 2026 WHO cervical cancer factsheet notes that national schedules may use one or two doses for girls aged 9–14. Because WHO and US recommendations are not identical, people should follow their own country’s approved vaccine schedule rather than assume that an online US schedule applies everywhere [3,5].
How many doses are needed?
| Situation | US CDC schedule |
|---|---|
| Started HPV vaccination before the 15th birthday and immunocompetent | 2 doses, usually separated by 6–12 months |
| Started on or after the 15th birthday (within recommended/eligible age groups) | 3 doses at 0, 1–2 and 6 months |
| Immunocompromised, including people with HIV, within the recommended eligible age group | 3 doses, even if started at ages 9–14 years |
The dose count depends on age when the series was started, not simply the person’s current age. Under the US two-dose schedule, doses given less than five months apart may require an additional dose. If a recommended interval is exceeded, the HPV vaccine series generally does not have to be restarted; the vaccinating clinician should review the documented doses and local rules [2].
WHO generally recommends at least two doses, and when feasible three, for people known to be immunocompromised or living with HIV. National recommendations vary according to policy, product and immune status [3,5].
Is HPV vaccination useful after someone becomes sexually active?
It can be. People may have been exposed to one HPV type but not other types contained in the vaccine. However, vaccination cannot eliminate an existing infection, reverse an abnormal HPV test, remove genital warts or treat precancerous lesions. The population-level benefit is greatest before sexual debut, which is why school-age vaccination is emphasized [2,3].
For adults aged 27–45, the likelihood of benefit varies. A clinician may discuss risk of future new HPV exposure, previous vaccination, immune status and preferences. Having a new sexual partner can increase the likelihood of future exposure; routine vaccination of everyone in this age group is not recommended by CDC [2].
Is HPV vaccination safe?
Extensive trials and post-licensure safety monitoring have found HPV vaccines to have a reassuring safety profile. Common reactions include temporary pain, redness or swelling at the injection site, and sometimes headache, dizziness or mild fever. Fainting can occur after injections, especially in adolescents, so it is appropriate to sit or lie down for approximately 15 minutes after vaccination [2,6].
Severe allergic reactions are very rare but require emergency treatment. A previous anaphylactic reaction to an HPV vaccine dose or a component is a contraindication. Some formulations have specific component-related precautions such as a severe immediate allergy to yeast. Consult product and local vaccination guidance [2,6].
Claims that HPV vaccination commonly causes infertility or permanent neurological injury are not supported by high-quality vaccine-safety monitoring. As with all vaccines, adverse-event signals continue to be investigated, but the well-established prevention benefits substantially outweigh the known risks for recommended recipients [6].
HPV vaccination and pregnancy
HPV vaccination is not recommended during pregnancy. If pregnancy is identified after the first dose, remaining doses should generally be postponed until after pregnancy. If a dose was given inadvertently during pregnancy, CDC advises that no special intervention is required solely because of that exposure; pregnancy testing is not required before vaccination [2,7]. Pregnant people should follow usual prenatal care and discuss concerns with their clinician.
Do vaccinated people still need cervical cancer screening?
Yes. HPV vaccination does not cover every oncogenic HPV type and is not a substitute for appropriate cervical screening. Vaccinated people with a cervix should follow their national cervical cancer screening recommendations, which may include high-risk HPV testing, cytology (Pap testing) or both, depending on age, test availability, prior results and risk [5].
The WHO’s July 2026 guidance stresses the importance of vaccination together with high-performance screening and timely treatment of precancerous lesions. Cervical screening recommendations can differ substantially by jurisdiction, especially for people with HIV or a history of abnormal screening [5]. A prior abnormal test does not automatically rule out vaccination when someone is otherwise eligible [3].
Practical ways to improve vaccine uptake
- Offer vaccination routinely at recommended ages rather than waiting for a discussion of sexual activity.
- Explain cancer prevention clearly and use respectful, evidence-based answers to safety questions.
- Use immunization records and reminders to complete the appropriate series.
- Offer vaccination equitably to eligible adolescents of all sexes where national policy permits.
- Integrate immunization counseling with other adolescent preventive services while maintaining confidentiality and informed consent.
Frequently asked questions
Can the HPV vaccine cause HPV infection?
No. HPV vaccines contain noninfectious virus-like particles without the viral genome and cannot cause HPV infection [3].
Why vaccinate children as young as nine?
Vaccinating before potential HPV exposure provides an opportunity for strong, durable protection against future infection and related cancers [2].
What if I missed the second or third dose?
Ask your vaccination provider to review the record. Under CDC guidance, the series usually does not need to be restarted after a longer-than-recommended interval [2].
Can an HPV vaccine cure genital warts or a positive HPV test?
No. HPV vaccines are preventive; treatment or surveillance of an existing HPV-related condition follows separate clinical guidance [3].
Is the vaccine only for girls?
No. HPV can cause cancer in people of different sexes; US routine vaccination includes boys and girls. Eligibility in other countries follows national policies [2,5].
Does vaccination mean cervical screening is unnecessary?
No. Vaccination and recommended cervical screening are complementary cancer-prevention approaches [5].
Key takeaways
HPV vaccination prevents future infections and many HPV-related cancers, especially when given before exposure. The schedule depends on age at the start, immune status and country. Vaccination does not treat an existing infection and does not replace recommended screening.
References
- Centers for Disease Control and Prevention. Clinical overview of HPV. Updated 9 Jul 2024.
- Centers for Disease Control and Prevention. HPV vaccine recommendations. Accessed 8 Nov 2026.
- World Health Organization. Human papillomavirus vaccines: WHO position and dosing guidance. Position paper Dec 2022.
- Centers for Disease Control and Prevention. Cancers caused by HPV. Accessed 8 Nov 2026.
- World Health Organization. Cervical cancer: fact sheet. Updated 3 Jul 2026.
- Centers for Disease Control and Prevention. HPV vaccine safety and effectiveness data. Accessed 8 Nov 2026.
- Centers for Disease Control and Prevention. Guidelines for vaccinating pregnant women. Updated 22 Aug 2025.
Medical disclaimer: This article is for educational use. Vaccine products, eligibility, dose schedules and screening recommendations vary by country and patient factors. Seek individual advice from a qualified immunization or healthcare professional.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.